Industry News & Blogs
Schizophrenia: Small Genetic Changes Pose Risk For Disease - 12/13/2011
Carrying single DNA letter changes from two different genes together may increase the risk of developing schizophrenia, Johns Hopkins researchers reported in the November 16 issue of Neuron.
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon | PRLog
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon. Global Antipsychotics Market Is Expected To Decline Due To Patent Expiries of Major Drugs - PR11777417
EnVivo Pharmaceuticals Inc Posts Positive Phase 2b
WATERTOWN, Mass. & WAIKALOA BEACH, Hawaii---- EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system
DSP and Takeda Sign Development and Commercialization Agreement for an Atypical Antipsychotic Agent
Dainippon Sumitomo Pharma Co., Ltd. (“DSP”) (Headquarters: Osaka, Japan: President: Masayo Tada) and Takeda Pharmaceutical Company Limited. (“Takeda”) (Headquarters: Osaka, Japan: President & CEO: Yasuchika Hasegawa) today announced that they have entered into a license agreement for the joint
Schizophrenia: NAMI Offers Public Education; Discusses New Research on Fish Oil and Marijuana
New website and brochure on schizophrenia launched by the National Alliance on Mental Illness
Medical News: Injectable No Better than Oral Antipsychotics - in Psychiatry, Schizophrenia from
Long-acting injectable risperidone (Risperdal Consta) was no more successful than oral antipsychotics in keeping patients with schizophrenia or schizoaffective disorder out of the hospital, a randomiz
Brain scans allow doctors to forecast schizophrenia - Scotsman.com News
Brain scans allow doctors to forecast schizophrenia - Brain scans could be used to help predict whether young people with a family history of schizophrenia will go on to develop the disease, a Scottish study suggests.<br />
Genetic Technology Alert. Engineered Erythropoietin Fusion Protein for Enhanced Delivery Across
This issue profiles engineered erythropoietin fusion protein for enhanced delivery across BBB, protein biomarker-based test for schizophrenia, and using keratinocytes derived from hESCs to create the epidermis. Strategic partnership details and some important patents have also been included.
Diminished pain perception in schizophrenia : The Lancet
Diminished pain perception in schizophrenia. By - Jie-Yu Chuang
Lilly Receives FDA Approval for Schizophrenia Drug -- Seeking Alpha
<strong><a href="http://register.zacks.com/ucd/step1.php?ALERT=alpha&ADID=ALPHA_content_welcome">Zacks.com</a>submits:</strong><p>Recently,<strong>Eli Lilly</strong>(<a href='http://seekingalpha.com/symbol/lly' title='More opinion and analysis of LLY'>LLY</a>) received US Food and Drug
Refine by Content Type:
Refine by Source:
- www.em-consulte.com (284)
- www.thelancet.com (201)
- download.thelancet.com (52)
- www.genengnews.com (26)
- www.webmd.com (23)
- www.biospace.com (19)
- www.hopkinsmedicine.org (18)
- www.medpagetoday.com (16)
- www.prlog.org (10)
- www.australiandoctor.com.au (9)
- www.medport.de (5)
- www.takeda.com (3)
